ABSTRACT
As an edible eukaryotic microorganism, Saccharomyces cerevisiae has the characteristics of high safety, rapid proliferation, low cost, easy transformation, etc. It has been widely used to produce vaccines, antibodies, insulin, etc. Up to now, yeast components, such as cell wall and yeast microcapsules, have been widely used in the treatment of tumors, inflammatory virus infection, post-traumatic osteoarthritis and other diseases. Among them, the components of yeast cell membrane are relatively simple and stable, which are easy to be extracted on a large scale. Therefore, yeast cell membrane material was used to construct yeast membrane vesicle nanosystem, and its biomedical application was preliminarily explored. In this study, Saccharomyces cerevisiae membrane vesicle (SMV) was prepared by co-extrusion method, and the particle size and surface potential of SMV, drug loading and release characteristics, stability, cell safety, and in vitro therapeutic effect were investigated. The results showed that the average particle size of SMV was 185.1 nm. Curcumin and silica nanoparticles were effectively encapsulated by co-incubation and ultrasonic methods, and the characteristics of cell membrane proteins were maintained. Moreover, SMV had good stability and biocompatibility. In addition, SMV could be effectively uptaken by macrophages RAW 264.7, and curcumin loaded SMV could effectively eliminate reactive oxygen species (ROS). In conclusion, the yeast plasma membrane vesicles prepared in this study could effectively deliver curcumin drugs and encapsulate nanoparticles, and could be effectively absorbed by macrophages and effectively eliminate ROS, providing new ideas and new methods for biomedical applications of yeast membrane materials.
ABSTRACT
Objective·To prepare a bacterial outer membrane vesicle (OMV) coated poly (lactic-co-glycolic acid) copolymer (PLGA) nanoparticle loaded with ovalbumin (OVA) and evaluate its intranasal immune effect in mice.Methods· OMV was prepared by ultrafiltration concentration method.OVA loaded PLGA nanoparticle (NP) was prepared by emulsion-solvent evaporation method.OMV coated PLGA nanoparticle (OMV-PLGA NP) loaded with OVA was prepared by extrusion method and characterized.BALB/c mice were intranasally immunized and specific sIgA levels in nasal wash,jejunum and fecal pellet were determined by ELISA.Results· Size of OVA loaded OMV-PLGA NP was (234.4±22.9) nm.The shell-core structure of OVA loaded OMV-PLGA NP was proved by transmission electron microscope.After 14 d of administration,sIgA antibody levels in nasal wash,jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group were the highest in all treated groups.Compared with the group treated with OMV and OVA,OVA-specific sIgA antibody level in nasal wash,jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group was increased 1.6,2.1 and 1.7 times,respectively.Compared with the group treated with OMV and OVA,OMV-specific sIgA antibody level in nasal wash,jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group was all increased 1.5 times.Conclusion· This novel nanoparticle drug delivery system can simultaneously delivery OVA and OMV to antigen presenting cells,resulting in stronger mucosal immune response in mice.
ABSTRACT
Objective: To prepare a bacterial outer membrane vesicle (OMV) coated poly (lactic-co-glycolic acid) copolymer (PLGA) nanoparticle loaded with ovalbumin (OVA) and evaluate its intranasal immune effect in mice. Methods: OMV was prepared by ultrafiltration concentration method. OVA loaded PLGA nanoparticle (NP) was prepared by emulsion-solvent evaporation method. OMV coated PLGA nanoparticle (OMV-PLGA NP) loaded with OVA was prepared by extrusion method and characterized. BALB/c mice were intranasally immunized and specific sIgA levels in nasal wash, jejunum and fecal pellet were determined by ELISA. Results: Size of OVA loaded OMV-PLGA NP was (234.4±22.9) nm. The shell-core structure of OVA loaded OMV-PLGA NP was proved by transmission electron microscope. After 14 d of administration, sIgA antibody levels in nasal wash, jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group were the highest in all treated groups. Compared with the group treated with OMV and OVA, OVA-specific sIgA antibody level in nasal wash, jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group was increased 1.6, 2.1 and 1.7 times, respectively. Compared with the group treated with OMV and OVA, OMV-specific sIgA antibody level in nasal wash, jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group was all increased 1.5 times. Conclusion: This novel nanoparticle drug delivery system can simultaneously delivery OVA and OMV to antigen presenting cells, resulting in stronger mucosal immune response in mice.
ABSTRACT
Ideal preparation of cancer therapy could specifically target to tumor cells, serving as safe and effective drug delivery system. With peculiar molecular recognition ability, aptamers become the most promising biological target molecules. This review was based on representative literatures, and the data was summarized and analyzed. It summarizes the latest research progress of aptamers modified targeted tumor preparation in the past five years from tethered way and carriers type, and the existing problems are analyzed and prospected.
ABSTRACT
As a new treatment strategy, immunotherapy has been leading oncotherapy into a new era, and cancer peptide vaccine has been developed as a promising prospect. In recent years applying nanoparticle drug delivery systems to the development of cancer peptide vaccines has became the research hotspot. As nanoparticle-based adjuvants, nanoparticle drug delivery systems can enhance immune response and therapeutic effect through various ways. In this review, we introduce the role of nanoparticle drug delivery systems in cancer peptide vaccines, particularly focusing on several kinds of nanoparticle drug delivery systems for improving immune response of cancer peptide vaccines. Finally, the challenges of applying nanoparticle drug delivery systems to deliver cancer peptide vaccines are preliminary analyzed, and the prospect is looked into.
ABSTRACT
Objective To analyze the current problems on tumor‐targeting nanoparticle drug delivery system .Methods Recent researches of tumor‐targeting nanoparticle drug delivery system were collected ,read and summarized .Results Three research fields on tumor‐targeting nanoparticle drug delivery system were reviewed in this article .Conclusion Not only a deeper understanding of the human physiology and tumor biology ,but changes in strategies and experimental methods are needed to make new achievements on nanoparticle drug delivery system .